• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Medtronic wins FDA approval for CareLink SmartSync CRM device manager

Medtronic wins FDA approval for CareLink SmartSync CRM device manager

May 2, 2019 By Brad Perriello

Medtronic logo updatedMedtronic (NYSE:MDT) said today that it won pre-market approval from the FDA for the CareLink SmartSync device manager for use with its cardiac rhythm management devices.

The approval gives the ability to use Apple iPads to program and manage data from pacemakers enabled with Medtronic’s BlueSync and an app that allows its Azure, Percepta, Serena, and Solara pacers to connect via BlueTooth.

“Medtronic is committed to developing smart technology solutions that help physicians seamlessly provide high-quality care to cardiac patients,” Dr. Rob Kowal, cardiac rhythm & heart failure CMO, said in prepared remarks. “SmartSync is another important innovation reinforcing that commitment. Clinicians will benefit from the portability that SmartSync offers and, because it was built to replicate the familiar CareLink 2090 interface, the transition to this new technology is quite simple.”

“The wireless capabilities and data transfer options of the SmartSync Device Manager have increased my efficiency in the lab and allow me to interact with my patients and peers more directly without sacrificing performance,” added Dr. Klaus Witte of the U.K.’s University of Leeds. “This type of portable device programing represents the future of cardiac data technology.”

Last October, Medtronic disabled internet updates for approximately 34,000 CareLink devices after the discovery of a vulnerability that could allow an outside agent to plant malware on the pacers to control or disable therapy. By March, the U.S. Homeland Security Dept. had warned of vulnerabilities in Medtronic devices using its Conexus radio frequency telemetry protocol, including some CareLink devices. At the time the company said it had already implemented additional controls covering the Conexus exploit and was developing further mitigations it expected to launch later this year pending FDA approvals.

Today Medtronic said it prioritized “high-level security design capabilities” for SmartSync.

“The security controls built into SmartSync and all BlueSync-enabled heart devices include multi-encryption, run time application monitoring for intrusion detection and access restrictions designed to protect the device and data transmissions,” the company said.

SmartSync won CE Mark approval in the European Union last year and is under limited release in the U.S., the company said. A full U.S. launch is slated for August.

Filed Under: Cardiovascular, Digital Health, Featured, Food & Drug Administration (FDA), Patient Monitoring Tagged With: Cardiac Rhythm Management, Medtronic

More recent news

  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure
  • Ambu wins FDA clearance for first single-use cysto-nephroscope
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy